07:48
2026-07-22
startupfortune.com
artificial-intelligence
Axiom Biosciences is skipping Nasdaq for Hong Kong and the math behind that call is hard to argue with
Axiom Biosciences, a San Diego-based clinical-stage biotech, plans a Hong Kong IPO in 2027 targeting at least $200 million, followed by a U.S. secondary listing in 2029, citing deep biotechnology capi…